Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration.
Safety data for anecortave acetate 15 mg suspension (Retaane 15 mg, Alcon Research, Ltd., Ft. Worth, TX 76134) as primary or adjunctive therapy with photodynamic therapy are available for 358 patients with age-related macular degeneration who received this novel cortisene during clinical trials in which the drug was administered via posterior juxtascleral depot every 6 months for 2 years. Detailed ophthalmic examinations, physical examinations, and adverse event reporting were used to characterize the clinical safety of anecortave acetate 15 mg and were monitored by an Independent Safety Committee. Anecortave acetate 15 mg was safe and well tolerated in the overall patient population. No serious, treatment-related deaths were reported. Ocular adverse events assessed as related to anecortave acetate 15 mg were non-serious with one exception (retinal detachment), mild to moderate in intensity with one exception, generally resolved with or without treatment, and did not interrupt patient participation in the studies with two exceptions. Anecortave acetate 15 mg is safe and well-tolerated when administered as a posterior juxtascleral depot at 6-month intervals for use as primary therapy or as adjunctive therapy with PDT.